80 related articles for article (PubMed ID: 22103071)
1. Toward preserving the structure of the antigenic peptide p17-1 from the HIV-1 p17 protein in nanostructured films.
Petri L; Ferreira M; Moraes ML
J Nanosci Nanotechnol; 2011 Aug; 11(8):6705-9. PubMed ID: 22103071
[TBL] [Abstract][Full Text] [Related]
2. Lignin as immobilization matrix for HIV p17 peptide used in immunosensing.
Cerrutti BM; Moraes ML; Pulcinelli SH; Santilli CV
Biosens Bioelectron; 2015 Sep; 71():420-426. PubMed ID: 25950938
[TBL] [Abstract][Full Text] [Related]
3. Antibody recognition of synthetic peptides mimicking immunodominant regions of HIV-1 p24 and p17 proteins.
Lottersberger J; Salvetti JL; Beltramini LM; Tonarelli G
Rev Argent Microbiol; 2004; 36(4):151-7. PubMed ID: 15786866
[TBL] [Abstract][Full Text] [Related]
4. Synthetic peptide AT20 coupled to KLH elicits antibodies against a conserved conformational epitope from a major functional area of the HIV-1 matrix protein p17.
Fiorentini S; Marsico S; Becker PD; Iaria ML; Bruno R; Guzmán CA; Caruso A
Vaccine; 2008 Aug; 26(36):4758-65. PubMed ID: 18602957
[TBL] [Abstract][Full Text] [Related]
5. Antibodies to the HIV-1 p17 protein cross-react with human superoxide dismutase-2.
Kato T; Suzuki J; Daimon M; Sasaki H; Ishikawa K
Biochem Biophys Res Commun; 1997 Jan; 230(1):184-7. PubMed ID: 9020042
[TBL] [Abstract][Full Text] [Related]
6. Identification of amino acid residues critical for the B cell growth-promoting activity of HIV-1 matrix protein p17 variants.
He W; Mazzuca P; Yuan W; Varney K; Bugatti A; Cagnotto A; Giagulli C; Rusnati M; Marsico S; Diomede L; Salmona M; Caruso A; Lu W; Caccuri F
Biochim Biophys Acta Gen Subj; 2019 Jan; 1863(1):13-24. PubMed ID: 30248376
[TBL] [Abstract][Full Text] [Related]
7. Pairwise decomposition of residue interaction energies of single chain Fv with HIV-1 p17 epitope variants.
Lee VS; Tue-ngeun P; Nangola S; Kitidee K; Jitonnom J; Nimmanpipug P; Jiranusornkul S; Tayapiwatana C
Mol Immunol; 2010 Feb; 47(5):982-90. PubMed ID: 20022377
[TBL] [Abstract][Full Text] [Related]
8. Solution X-ray scattering reveals a novel structure of calmodulin complexed with a binding domain peptide from the HIV-1 matrix protein p17.
Izumi Y; Watanabe H; Watanabe N; Aoyama A; Jinbo Y; Hayashi N
Biochemistry; 2008 Jul; 47(27):7158-66. PubMed ID: 18553937
[TBL] [Abstract][Full Text] [Related]
9. Gag-derived proteins of HIV-1 isolates from Indian patients: cloning, expression, and purification of p17 of B- and C-subtypes.
Gupta S; Arora K; Gupta A; Chaudhary VK
Protein Expr Purif; 2001 Apr; 21(3):378-85. PubMed ID: 11281711
[TBL] [Abstract][Full Text] [Related]
10. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
11. Immunosensor based on immobilization of antigenic peptide NS5A-1 from HCV and silk fibroin in nanostructured films.
Moraes ML; Lima LR; Silva RR; Cavicchioli M; Ribeiro SJ
Langmuir; 2013 Mar; 29(11):3829-34. PubMed ID: 23414139
[TBL] [Abstract][Full Text] [Related]
12. Immunosensor for HIV-1 diagnostics based on immobilization of the antigenic peptide p24-3 into liposomes.
Moraes ML; Rodrigues VC; Soares JC; Ferreira M; de Souza NC; Oliveira ON
J Nanosci Nanotechnol; 2014 Sep; 14(9):6638-45. PubMed ID: 25924310
[TBL] [Abstract][Full Text] [Related]
13. Flexible and rigid structures in HIV-1 p17 matrix protein monitored by relaxation and amide proton exchange with NMR.
Ohori Y; Okazaki H; Watanabe S; Tochio N; Arai M; Kigawa T; Nishimura C
Biochim Biophys Acta; 2014 Mar; 1844(3):520-6. PubMed ID: 24373876
[TBL] [Abstract][Full Text] [Related]
14. Cross-reactivity of anti-HIV-1-p17-derivative peptide (P30-52) antibody to Env V3 peptide.
Ota A; Tanaka-Taya K; Ueda S
Hybridoma; 1999 Apr; 18(2):149-57. PubMed ID: 10380014
[TBL] [Abstract][Full Text] [Related]
15. Total chemical synthesis of N-myristoylated HIV-1 matrix protein p17: structural and mechanistic implications of p17 myristoylation.
Wu Z; Alexandratos J; Ericksen B; Lubkowski J; Gallo RC; Lu W
Proc Natl Acad Sci U S A; 2004 Aug; 101(32):11587-92. PubMed ID: 15280532
[TBL] [Abstract][Full Text] [Related]
16. Characterization of mother-infant HIV type 1 gag p17 sequences associated with perinatal transmission.
Hahn T; Matala E; Chappey C; Ahmad N
AIDS Res Hum Retroviruses; 1999 Jul; 15(10):875-88. PubMed ID: 10408724
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
[TBL] [Abstract][Full Text] [Related]
18. Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17.
Zimmerman DH; Ulrich JT; Wright C; Lloyd JP; Winship MD; Sarin PS
AIDS Res Hum Retroviruses; 1998 Jun; 14(9):741-9. PubMed ID: 9643374
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 matrix protein p17 misfolding forms toxic amyloidogenic assemblies that induce neurocognitive disorders.
Zeinolabediny Y; Caccuri F; Colombo L; Morelli F; Romeo M; Rossi A; Schiarea S; Ciaramelli C; Airoldi C; Weston R; Donghui L; Krupinski J; Corpas R; García-Lara E; Sarroca S; Sanfeliu C; Slevin M; Caruso A; Salmona M; Diomede L
Sci Rep; 2017 Sep; 7(1):10313. PubMed ID: 28871125
[TBL] [Abstract][Full Text] [Related]
20. Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag.
de Goede AL; Boers PH; Dekker LJ; Osterhaus AD; Gruters RA; Rimmelzwaan GF
Vaccine; 2009 Sep; 27(42):5735-9. PubMed ID: 19647812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
